2026-10-27 Regulation Bear
Court denies Novo Nordisk injunction, Lilly GLP-1 ads can continue Judge rules Lilly's ads don't violate false advertising laws, a setback for Novo's lawsuit
D1 -1.2% · +5d +3.9%
2026-10-20 Product Bull
CagriSema shows 25% weight loss in women in late-stage analysis New data suggests improved efficacy over Wegovy, bolstering obesity pipeline
D1 +2.4% · +5d -1.7%
2026-10-02 → 10-05 Regulation Bear
FDA Delays Denecimig Review on Facility Remediation; Novo Hemophilia Drug Launch Pushed Back Delay due to manufacturing remediation, not clinical efficacy/safety issues; timeline impacted
D1 -0.2% · +5d +3.5%
› 2 waves of this story2026-10-02 FDA says review ongoing, approval timeline uncertain, impacting hemophilia pipeline outlook2026-10-05 Delay due to manufacturing remediation, not clinical efficacy/safety issues; timeline impacted2026-10-03 Product Bear
Lilly Oral Data Adds Pressure; Novo Nordisk Faces Intensified Obesity Competition Lilly's mid-stage data shows better weight loss than tirzepatide, pressuring Novo's oral obesity franchise
D1 +0.6% · +5d +2.8%
2026-09-29 → 10-01 Product Bull
Novo's Ozempic 2mg Shows Lower CV Risk vs Mounjaro COMPETE SWITCH study shows 6% lower MACE risk vs Mounjaro
D1 -1.0% · +5d -2.0%
› 2 waves of this story2026-09-29 Real-world evidence supports higher Ozempic dose, potentially impacting GLP-1 competitive dynamics2026-10-01 COMPETE SWITCH study shows 6% lower MACE risk vs Mounjaro2026-09-29 Company
Novo Nordisk inks up to $2.6B licensing deal with Hengrui for oral obesity drug Adds phase 1-ready once-weekly oral GLP-1/GIP dual agonist to bolster obesity pipeline amid competition
D1 -1.0% · +5d -2.0%
2026-09-25 Company Bull
Novo Nordisk signs $1.3B licensing deal with Nanexa for injection tech Technology could cut injection frequency for obesity and diabetes drugs, boosting NVO's pipeline
D1 +0.5% · +5d -3.8%
2026-09-24 Regulation Bull
Novo Nordisk Receives Positive EU Regulatory Recommendations, Expanding Rare Disease Pipeline Positive CHMP opinions for Frehemgo and Sogroya, potentially diversifying revenue
D1 +1.2% · +5d -3.2%
2026-09-23 Capital
CEO Open to Direct NYSE Listing to Boost US Presence US accounts for over half of revenue; direct listing may increase visibility
D1 -3.1% · +5d -0.7%
2026-09-23 Company
Novo CEO: Pills could capture 50% of weight-loss market by 2030 CEO's outlook underscores oral strategy amid Lilly competition and patent cliff
D1 -3.1% · +5d -0.7%
2026-09-21 Product Bull
Novo Nordisk's CagriSema Shows Superior Weight Loss vs Tirzepatide in Phase 5 Trial CagriSema achieved 12.4% weight loss vs 9.1% for tirzepatide in REIMAGINE 5 trial.
D1 -8.0% · +5d -2.7%
2026-09-17 → 09-19 Regulation Bull
Novo's Denecimig Gets EU CHMP Positive Opinion EU regulator backs hemophilia A treatment, potentially expanding Novo's portfolio
D1 +3.5% · +5d -10.6%
› 2 waves of this story2026-09-17 Key regulatory nod advances hemophilia pipeline amid competition and patent pressures2026-09-19 EU regulator backs hemophilia A treatment, potentially expanding Novo's portfolio2026-09-17 Capital Bull
Novo Nordisk, Orbis Sign Up to $1.4B Oral Drug Deal Expands oral macrocyclic peptide therapies, bolstering cardiometabolic pipeline
D1 +3.5% · +5d -10.6%
2026-09-17 Company
Novo Nordisk partners with Anthropic for AI-driven drug discovery Deploys frontier AI models across R&D and software engineering to speed drug development
D1 +3.5% · +5d -10.6%
2026-09-16 Product Bear
Lilly's Oral GLP-1 Captures 30%+ New US Patients, Pressuring Novo's Oral Share Lilly claims 30%+ of new US oral GLP-1 patients; Novo's Wegovy pill previously held ~90% of US oral obesity market
D1 -1.9% · +5d -8.5%
2026-09-14 → 09-15 Company Bear
Novo Nordisk Rebrands to Novo; CEO Urges Customer Focus, Shares Fall 2% CEO pushes customer-centric culture post-rebrand; analyst says move fails to ease competition and pricing headwinds
D1 +0.9% · +5d -8.4%
› 2 waves of this story2026-09-14 Day-to-day name changes to Novo to boost recognition amid obesity market share loss.2026-09-15 CEO pushes customer-centric culture post-rebrand; analyst says move fails to ease competition and pricing headwinds2026-09-12 → 09-14 Analyst Bear
Morgan Stanley downgrades Novo to Underweight on patent, rivalry woes MS cuts to Underweight citing muted growth, patent risks, Lilly pressure.
D1 +0.9% · +5d -8.4%
› 2 waves of this story2026-09-12 Analysts worry semaglutide to be 75% of 2026 sales, patent cliff looms2026-09-14 MS cuts to Underweight citing muted growth, patent risks, Lilly pressure.2026-09-11 Analyst
Morgan Stanley downgrades to Underweight D1 -2.1% · +5d +0.4%
2026-09-10 Product Bull
Novo Nordisk's Wegovy approved in China for MASH liver disease First GLP-1 approved in China for MASH, expanding Wegovy's indications
D1 -1.2% · +5d -1.9%
2026-09-07 → 09-09 Product
Novo's Semaglutide Hits Pediatric Obesity Goal Amid Competitive Pressures Phase III STEP Young shows BMI reduction in obese children aged 6-12, 40.4% no longer obese; faces Lilly competition and patent cliffs
D1 -3.1% · +5d -5.8%
› 2 waves of this story2026-09-07 Two independent reports confirm primary endpoint met in children 6-12, potentially expanding Wegovy's label2026-09-09 Phase III STEP Young shows BMI reduction in obese children aged 6-12, 40.4% no longer obese; faces Lilly competition and patent cliffs2026-09-08 Company Bear
Novo Nordisk halts two more heart drug trials, diversification setback Two ziltivekimab trials halted, underscoring reliance on obesity franchise for growth
D1 -3.1% · +5d -5.8%
2026-09-01 → 09-03 Product
Novo Nordisk's Oral Wegovy Launches in Germany, Zava Begins Delivery Zava confirms delivery of oral Wegovy in Germany, aligning with EU-first launch and advancing commercialization
D1 -0.5% · +5d -1.2%
› 2 waves of this story2026-09-01 Oral Wegovy launched in Germany, first EU country, expanding weight-loss drug market reach2026-09-03 Zava confirms delivery of oral Wegovy in Germany, aligning with EU-first launch and advancing commercialization2026-09-02 → 09-03 Regulation
FDA Warns on Compounded GLP-1 Risks, Novo Nordisk in Focus FDA cites 30 firms, HIMS falls, LLY and NVO in focus
D1 +3.7% · +5d -5.9%
› 2 waves of this story2026-09-02 FDA warning letters ban retatrutide and cagrilintide in compounding, impacting GLP-1 market2026-09-03 FDA cites 30 firms, HIMS falls, LLY and NVO in focus2026-08-28 Analyst Bear
Deutsche Bank downgrades Novo Nordisk to Sell, shares down 70% from peak Growth concerns mount; Wall Street had been reluctant to advise selling
D1 -1.4% · +5d +2.2%
2026-08-14 → 08-26 Product
China regulator accepts oral Wegovy application; competition persists After Lilly oral approval, Novo advances oral weight-loss drug in China
D1 -1.8% · +5d +1.9%
› 2 waves of this story2026-08-14 Eli Lilly's Foundayo, Europe's first oral GLP-1 approval with no food restrictions, directly challenges Novo Nordisk's oral Wegovy2026-08-26 After Lilly oral approval, Novo advances oral weight-loss drug in China2026-08-10 → 08-19 Company
Novo Nordisk Starts Study for Lowest Effective Wegovy Pill Dose New study tests lower doses, potentially expanding oral weight-loss drug access
D1 +1.0% · +5d -6.0%
› 4 waves of this story2026-08-10 Co-innovation hub in London to accelerate drug discovery2026-08-11 Oral GLP-1 competition intensifies; OASIS 5 start and UK approval of Lilly's pill both impact NVO's market position2026-08-11 Phase 3 trial for oral weight-loss drug expands pipeline amid competitive pressure.2026-08-19 New study tests lower doses, potentially expanding oral weight-loss drug access2026-08-12 Analyst Bear
Berenberg Cuts Novo Nordisk to Hold, PT Lowered to $47 Analyst sees further multiple expansion requiring proof of obesity-pill lead and injectable growth
D1 -1.7% · +5d +0.2%
2026-08-11 Capital Bear
First Trust Advisors Cuts Novo Nordisk Stake by 94.5% in Q1 Institutional selling signals caution on Novo Nordisk's near-term outlook.
D1 -1.2% · +5d -3.1%
› 2 waves of this story2026-08-11 Institutional 13F filing shows major stake reduction, reflecting institutional flows2026-08-11 Institutional selling signals caution on Novo Nordisk's near-term outlook.
